Letter to the Editor: sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis

Yusra Hidayat

doi:10.1080/09546634.2026.2690324

June 18, 2026Journal of Dermatological TreatmentOpen Access

Letter to the Editor: sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis

View Full Paper

Ask AI

Bookmark

Share

Key Points

This analysis aims to evaluate the long-term effectiveness of abrocitinib in managing moderate-to-severe atopic dermatitis.
Post-hoc analysis of data from clinical trials on abrocitinib.
Focused on patients with moderate-to-severe atopic dermatitis.
Assessment of flare frequency based on protocol-defined criteria.
21.3% of patients remained free of flares while on abrocitinib treatment.
Observations suggest prolonged disease control during treatment periods.

Implication

Demonstrates sustained disease control in moderate-to-severe atopic dermatitis, indicating therapeutic promise for patients.

Abstract

We read with great interest the post-hoc analysis by Guttman-Yassky et al. reporting that 21.3% of patients with moderate-to-severe atopic dermatitis (AD) remained free of protocol-defined flare fo...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yusra Hidayat (2026) studied this question.

synapsesocial.com/papers/6a362f92db0793dc1a536f03 https://doi.org/10.1080/09546634.2026.2690324

View Full Paper

Ask AI

Bookmark

Share

Letter to the Editor: sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis

Key Points

Implication

Abstract

Discussion

Cite This Study

Letter to the Editor: sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading